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Abstract. Controlled human malaria infections (CHMIs) with Plasmodium falciparum (Pf ) parasites are well estab-
lished. Exposure to ﬁve Pf (NF54)-infected Anopheles mosquitoes results in 100% infection rates in malaria-naı¨ve vol-
unteers. Recently Pf clones NF135.C10 and NF166.C8 were generated for application in CHMIs. Here, we tested the
clinical infection rates of these clones, using graded numbers of Pf-infected mosquitoes. In a double-blind randomized
trial, we exposed 24 malaria-naı¨ve volunteers to bites from one, two, or ﬁve mosquitoes infected with NF135.C10 or
NF166.C8. The primary endpoint was parasitemia by quantitative polymerase chain reaction. For both strains, bites by
ﬁve infectedmosquitoes resulted in parasitemia in 4/4 volunteers; 3/4 volunteers developedparasitemia after exposure to
one or two infected mosquitoes infected with either clone. The prepatent period was 7.25 ± 4.0 days (median ± range).
There were no serious adverse events and comparable clinical symptoms between all groups. These data conﬁrm the
eligibility of NF135.C10 and NF166.C8 for use in CHMI studies.
INTRODUCTION
Controlled human malaria infections (CHMIs) are a well-
accepted tool used since the 1980s for the exploration of
immunology and pathophysiology of malaria infections and
for evaluation of candidate vaccines and drugs.1 The majority
of studies have been conducted with 3D7 and its parental
strain NF54.1 Most volunteers have been infected using ﬁve
laboratory-reared Plasmodium falciparum (Pf )–infected
Anopheles mosquitoes, which reproducibly result in optimal
infection rates in malaria-naı¨ve volunteers.2,3 Reducing the
number of NF54 or 3D7 Pf-infected mosquitoes to one or two
reduces the infection rate.4,5
Given the diversity ofPf isolates in the ﬁeld, the value of CHMI
trials can be increased by expanding the portfolio with Pf clonal
isolates fromdifferent geographical origins.6 ThePf isolate NF54,
most likely originates from Africa.7 The more recently generated
clones are NF135.C10 and NF166.C8, originating from Cambo-
dia and Guinea, respectively. Initial studies with NF135.C10 and
NF166.C8show that theseclonesaresafe andgivehigh infection
rateswith ﬁve infectiousmosquitoes (80% [8/10] and100% [5/5],
respectively).8,9 However, these clones show more effective he-
patocyte invasion and livermerozoite development as compared
with NF54, which results in higher ﬁrst peak of parasitemia and
shorterprepatentperiod.10 Inorder toestablishanNF135.C10-or
NF166.C8 CHMI model with comparable parasite dynamics as
obtained inNF54-infected volunteers, the objective of the current
study was to compare infection rates and dynamics of para-
sitemia as well as clinical manifestations using one, two or ﬁve
NF135.C10- or NF166.C8- infected mosquitoes.
MATERIALS AND METHODS
The study is a single-center, double-blind, randomized trial.
The ﬂowchart, screening procedures, and inclusion and
exclusion criteria were described previously.10 Brieﬂy, 24
healthy male and female volunteers, aged 18–35 years, were
randomly assigned to six groups and exposed to bites from
ﬁve mosquitoes of which ﬁve, two, or one were infected with
either NF135.C10 or NF166.C8. Uninfected mosquitoes were
added topreserveblindingof all trial personnel except the staff
members preparing and aliquotting infected mosquitoes.
Anopheles stephensimosquitoes were reared and infected
according to standardized protocols.11,12 The average num-
ber of sporozoites permosquito used in this studywas 69,000
for NF135.C10 and 51,000 for NF166.C8. Mosquito feeding
was allowed for 10 minutes and infectivity of mosquitoes was
assessed after feeding by dissecting salivary glands for the
presence of sporozoites. Feeding was repeated until the
predeﬁned number of infected bites was reached. Eight vol-
unteers needed two sessions, one needed three sessions (all
in the ﬁve- or two-mosquito bite groups).
After CHMI, volunteers were followed-up twice daily from
day 5 post-infection until two consecutive blood samples
were positive by quantitative polymerase chain reaction (qPCR)
(³500parasites/mL),or,whentheyremainednegative,untilday13.
At this point, volunteers were treated with atovaquone/proguanil
and followed on days 1, 2, 3, and 7 after treatment and on day 35
post-infection. Follow-up was prolonged if volunteers remained
qPCR-positive or symptomatic. Throughout the study, high-
sensitive troponin T, lactate dehydrogenase (LDH), and platelet
counts were measured as safety parameters. The ﬁrst peak of
parasitemiawascalculatedas thegeometricmeanofPfparasites
per milliliter between day 6.4 and 8.4.13
The trial was registered at www.clinicaltrials.gov, identiﬁer
NCT02149550. Ethical approval from the Central Committee
on Research Involving Human Subjects (NL48704.000.14)
was obtained.
All statistical analyses were performed with IBM SPSS
statistics forWindows (Version 23.0; IBMCorp., Armonk, NY).
Mean prepatent period, ﬁrst peak of parasitemia, and the
frequency of adverse events (AEs) between the groups were
assessed by using unpaired t test, one-way analysis of
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variance (ANOVA), or their nonparametric variants. Adverse
events were reported as mild (grade 1), moderate (grade 2), or
severe (grade 3).
RESULTS
In total, 20 of 24 volunteers developed parasitemia; all vol-
unteers exposed to ﬁve infected mosquitoes and 3/4 volun-
teers exposed to one or two infected mosquitoes with either
strain (Table 1).
The prepatent period in the NF135.C10 groups ranged from
7 to 9 days and did not differ signiﬁcantly between the dosage
groups (median [range] ﬁve mosquitoes: 7.5 [7.0–9.0] versus
two mosquitoes: 9.0 [7.5–9.0] versus one mosquito: 7.0
[7.0–7.0]; P = 0.06, Table 1). There was no difference in ﬁrst
peak of parasitemia in parasites/mL (geometric mean (GM)
[95% conﬁdence interval (CI)] ﬁve mosquitoes: 2.9 [1.8–4.0],
versus two mosquitoes: 2.4 [1.0–3.8], versus one mosquito:
3.0 [2.3–3.7]; P = 0.32) (Figure 1A). All parasitemic volunteers
experienced one or more AEs. When comparing subjects
challenged with either ﬁve, two, or one NF135.C10-infected
mosquitoes, there were no differences in the total number of
grade 1, 2, or 3 AEs (P = 0.81, P = 0.60, and P = 0.87, re-
spectively) (Figure 1B), or the number of solicited AEs (head-
ache, nausea, malaise, chills and myalgia, data not shown). A
few unsolicited AEs were reported, two or three per group, all
grade 1.
For the NF166.C8 clone, no signiﬁcant difference was
found in the prepatent period between the three dosage
groups either (median [range] ﬁve mosquitoes: 7.0 [7.0–7.0]
versus two mosquitoes: 7 [7.0–11.0] versus one mosquito:
9.0 [7.5–9.0];P= 0.09, Table 1). In contrast toNF135.C10, the
ﬁrst peakof parasitemiawas signiﬁcantly higher in volunteers
bitten by higher numbers of NF166.C8-infected mosquitoes
(GM [95% CI] ﬁve mosquitoes: 3.8 [3.3–4.2], versus two
mosquitoes: 2.4 [−0.9 to 5.6], versus one mosquito: 2.2
[1.7–2.7]; P = 0.04, Figure 2A). There were no differences in
the number of grade 1, 2, or 3 AEs (P = 0.11, P = 0.33, and P =
0.90, respectively) (Figure 2B), nor in the number of solicited
AEs between the volunteers challenged with either ﬁve, two,
or one NF166.C8-infected mosquitoes (data not shown). A
few unsolicited AEs were reported, four or six per group, all
grade 1.
When comparing all subjects who developed parasitemia
with either strain, the prepatent period was similar for NF135.
C10 and NF166.C8 (median [range] 7.5 [7.0–9.0] versus 7.0
[7.0–11.0]; P = 0.65 see Table 1) as was the height of the ﬁrst
peak of parasitemia (GM [95% CI] NF135.C10: 2.8 [2.4–3.2]
parasites/mL versus NF166.C8: 2.9 [2.1–3.6]; P = 0.48). In
addition, therewere no signiﬁcant differences in the number of
grade 1, grade 2, or grade 3 AEs between the two strains (P =
0.91, P = 0.07, P = 0.96).
Upon antimalarial drug treatment, LDH was elevated (> 248
U/L, max 499 U/L) in 10 (50%) malaria-positive volunteers.
Platelets were decreased (< 150 × 109/L, min 85 × 109/L) in 11/
20. Therewasno relationwith thePf-clone usedor the number
of bites, and these changes in safety parameters were
deemed clinically insigniﬁcant. The changes normalized by
the end of the study. Throughout the trial hs-troponin T
remained lower than 14.0 ng/L in all volunteers.
TABLE 1
The number of volunteers developing parasitemia and the prepatent period in days after infection with graded numbers of NF135.C10- or
NF166.C8- infected mosquitoes
No. of infectious bites
P valueFive, two, or one Five Two One
Strain NF135.C10 Subjects PCR positive (n/total) 10/12 4/4 3/4 3/4 –
Prepatent period (days (median [range])) 7.5 [7.0–9.0] 7.5 [7.0–9.0] 9.0 [7.5–9.0] 7.0 [7.0–7.0] 0.06
NF166.C8 Subjects PCR positive (n/total) 10/12 4/4 3/4 3/4 –
Prepatent period (days (median [range])) 7.0 [7.0–11.0] 7.0 [7.0–7.0] 7.0 [7.0–11.0] 9.0 [7.5–9.0] 0.09
Differences between groups were tested using the Kruskal–Wallis method.
FIGURE 1. Comparison of one, two, and ﬁve NF135.C10-infected
mosquito bites (A). Kinetics of parasitemia in Pf/mL (log) at days post-
controlled human malaria infection until qPCR positive (two consec-
utive samples > 500 Pf/mL). Data represent the geometric means and
error bars. (B). Number of graded adverse events (AE) per volunteer.
Symbols represent individual volunteers, and horizontal lines and
whiskers represent median and range, respectively. Pf = Plas-
modium falciparum.
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DISCUSSION
This study shows that CHMI with ﬁve bites of NF135.C10- or
NF166.C8-infectedmosquitoesresults in100%patentparasitemia,
which is comparable with the outcomes of previous CHMIs with
NF54, 3D7,or 7G8.3,14,15 Lowering thenumberof infectiousbitesof
bothtestclonestooneortwobitesreducedthepatencyto75%(3/4
individuals infected), which is similar to previous trials with 3D7-or
NF54-infected mosquitoes showing parasitemia in 40–60% of the
cases.4,5
The kinetics of emerging NF135.C10 parasitemia remained
relatively similar irrespective of the number of infected mos-
quitoes used. Theoretically, a relation with the number of in-
fectiousmosquito bites could be expected, as seen in NF166.
C8. However, the variance in ﬁrst peak of parasitemia, in
NF135.C10,was large, and these small groups did not allow to
ﬁnddifferences.Parasite release fromthe livermaybesubject to
variation in sporozoite numbers delivered by the blood-feeding
mosquitoes. We previously estimated from CHMI studies that
on average 21 sporozoites per mosquito infect hepatocytes,
whereas others estimated a release in the range of 1–369 per
mosquito.16,17 In addition, the probability of infectiondecreases
with a lower sporozoite load (0–1,000) per mosquito.18 How-
ever, in our studies mosquitoes are infected with > 25,000
sporozoites/mosquito where no such relation exists.19
Differences in patencybetweenone, two, orﬁve infectedbites
suggest there is a strain-independent threshold to be overcome
before successful infection occurs which can stochastically
result in zero successful events. Such bottlenecks may include
the frequency of mosquito probing, the number of sporozoites
entering the blood stream, and the number that invade hepato-
cytes. After hepatocyte invasion, the efﬁciency of parasite mul-
tiplication may differ between strains with a potential higher ﬁrst
peak of parasitemia and correspondingly shorter prepatent pe-
riods for NF135.C10 and NF166.C8. This difference in multipli-
cation inside hepatocytes is unlikely related to differences in
ﬁtness of these clones, as the IC50 of CSP-antibodies blocking
in vitro hepatocyte development is comparable.9
Data from this and other studies with NF135.C10- and
NF166.C8-infected volunteers showed that there is no
increase in the number or severity of AEs compared with
NF54-infected volunteers, despite the higher ﬁrst peak of
parasitemia.10 The prevalence and severity of AEs will likely
further reduce if antimalarial treatment is initiated upon more
stringent qPCR cut-off values.20
In conclusion, this study with limited numbers of volunteers
per group shows that bites of ﬁve mosquitoes of NF135.C10
and NF166.C8 of either clone consistently gives 80–100%
patent parasitemia in the three studies performed with these
heterologous clones. In future CHMI studies using clones
NF135.C10 and NF166.C8 and lower numbers of mosquito
bites may sufﬁce to achieve blood-stage dynamics which are
more similar to NF54, albeit reaching lower infection rates.
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